The Cambridge ECMC aims to develop molecular prognostic and diagnostic tests to aid treatment decisions. The Centre focuses on genetic predisposition to cancer and the identification of high risk groups. This is being achieved by building on local strengths in genomics, pharmacogenetics, molecular pathology, molecular imaging, clinical informatics and computational biology.
Experimental Cancer Medicine Centres (ECMC) researchers are world-leading scientists and clinicians who drive the discovery, development and testing of new treatments to combat cancer. The funding supports over 200 staff involved in early phase trials and translational research. The ECMC Network is made of up 18 Centres across the UK. There are adult and paediatric Centres. Find out more about the Centres.
The Cambridge ECMC underpins all clinical trial activity within the CRUK Cambridge Centre, providing the vision and critical infrastructure necessary to translate our science into patient benefit. The Cambridge ECMC has focused on early phase clinical trials (EPCTs) and the discovery and development of cancer biomarkers and devices to characterise both the patient and their cancer.
Since 2012 the Cambridge ECMC has overseen the treatment of 7,740 cancer patients on over 230 clinical trials; 91 of these studies were supported directly by the Cambridge ECMC. All trials were conducted within the Cambridge University Hospitals NHS Foundation Trust (CUH).
Find out more about the Cambridge ECMC programme here.
Cancer control will ultimately be achieved through prevention, through early diagnosis, through better use of currently available treatments, and through the development of new better targeted therapeutics. The Cambridge ECMC provides support related to each of these areas. In particular, the Cambridge ECMC provides infrastructure support for 6 broad research areas:
- Early-phase clinical trials and experimental therapeutics
- Tumour monitoring (advanced cancer imaging)
- Tumour monitoring (liquid biopsy, cfDNA)
- Predictive biomarkers
- Translational research in late-phase trials
- Screening and intervention in high-risk groups